3 ASX 200 shares for smart investors to buy

Analysts think these shares could be smart buys this month. Let's find out why.

Smart investors know that long-term wealth isn't built on hype — it is built by owning quality businesses with real earnings power, global opportunity, and the ability to compound growth over time.

Right now, a handful of ASX 200 shares are quietly delivering just that and analysts think they could be top buys.

With that in mind, here are three ASX 200 shares that smart investors may want to have on their radar.

Suncorp share price Businessman cheering and smiling on smartphone

Image source: Getty Images

James Hardie Industries plc (ASX: JHX)

This ASX 200 share has long been a favourite of investors looking for exposure to the US housing and renovation market — and for good reason. James Hardie is a global leader in fibre cement and building solutions, with strong brand recognition and a footprint that spans North America, Europe, and the Asia Pacific.

Bell Potter thinks that now could be a great time to invest. It believes that "JHX is poised for continued earnings expansion, driven by the structural shift towards fibre cement in the US. Households in the US continue to shift to fibre cement cladding from vinyl/timber, providing a multi-year runway for JHX's revenue and profit growth."

In light of this, the broker has put a buy rating and $63.00 price target on its shares.

ResMed Inc. (ASX: RMD)

ResMed could be another ASX 200 share for smart investors to buy. It is the global leader in sleep apnoea treatment and respiratory care, with a growing digital health ecosystem that improves patient outcomes and drives recurring revenue.

Concerns about the impact of weight-loss drugs like GLP-1s have weighed on the share price in recent times, but ResMed continues to deliver earnings growth, expand its cloud-based software platform, and gain market share across key regions. In fact, the company believes they could be a positive and increase awareness and expand its addressable market.

Goldman Sachs is very positive on the company's outlook. So much so, it has a conviction buy rating and $49.30 price target on ResMed's shares.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix isn't yet a household name — but it could be soon. This clinical-stage biotech has emerged as one of the most promising players in the radiopharmaceuticals space, developing targeted therapies and diagnostics for cancer treatment.

Its lead product, Illuccix, is already approved and generating revenue in prostate cancer imaging, and the company has a growing pipeline of next-generation treatments.

While still early-stage compared to big pharma, Telix is executing commercially and scientifically, making it one of the most exciting growth stories on the Australian share market.

It is for this reason that Bell Potter has a buy rating and $34.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Happy investor on tablet with finance graphs rising in overlay.
Growth Shares

Could these 3 ASX shares grow into $100 billion companies by 2036?

I wouldn't rule out any of these three companies reaching this milestone, although I'd be much more confident backing one…

Read more »

Two men sit side by side on a couch with video game controls in their hands and expressive looks on their faces.
Growth Shares

3 ASX growth shares almost as exciting as the GTA 6 release

It is a great time to be a gamer. But are these shares just as exciting?

Read more »

Happy young couple riding a motorbike together.
Growth Shares

3 ASX shares I think could be worth twice as much in 5 years

These shares appear well-placed for growth over the next half-decade.

Read more »

Happy businessman fist pumping while looking at a tablet.
Growth Shares

Why WiseTech and these ASX growth shares make my shortlist for 2027

There are reasons to be positive on these growing companies.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Growth Shares

Could this ASX 200 share turn $10,000 into $20,000 by 2030?

The company already has an impressive global presence, but I think there's still plenty of room to grow.

Read more »

Two shop workers smiling and looking at a laptop surrounded by plants.
Growth Shares

The ASX's next great growth stock? I've narrowed my shortlist to two

These companies have already made impressive progress, but I think there's still a lot more they could achieve.

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Growth Shares

2 ASX shares highly recommended to buy: Experts

Multiple brokers are excited about these ideas.

Read more »

A couple sits on the bed in their hotel room wearing white robes, with both having seen bad news on their phones.
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

This business is delivering significant financial growth.

Read more »